Know Cancer

forgot password

Chemoprevention for Barrett's Esophagus Trial (CBET)

Phase 2
18 Years
Not Enrolling
Esophageal Cancer

Thank you

Trial Information

Chemoprevention for Barrett's Esophagus Trial (CBET)


- Determine the safety and efficacy of celecoxib for regression of Barrett's dysplasia in
patients with low or high-grade dysplasia of the esophagus.

OUTLINE: This is a randomized, parallel, double-blind, placebo-controlled, multicenter
study. Patients are stratified according to center and grade of dysplasia at baseline (low
vs high). Patients are randomized to one of two treatment arms.

- Arm I: Patients receive oral celecoxib twice daily for 48-96 weeks.

- Arm II: Patients receive oral placebo as in arm I. Treatment continues in both arms in
the absence of unacceptable toxicity or development of adenocarcinoma of the esophagus
or cancer at other sites.

Patients are followed at 12 weeks.

PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study.

Inclusion Criteria


- Histologically confirmed Barrett's dysplasia with specific information on the
location (level) of the highest grade of dysplasia based on biopsy from baseline

- Short segment Barrett's esophagus must be sufficient area to allow for biopsy
without complete resection

- No presence of reflux esophagitis grades 2-4

- No history of confirmed invasive carcinoma of the esophagus

- No diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration of 1 cm
or more in diameter within the past 30 days



- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- Not specified


- Hemoglobin at least 9 g/dL

- Platelet count greater than 125,000/mm^3

- WBC greater than 3,000/mm^3

- No significant bleeding disorder

- No other abnormal hematopoietic laboratory test result that would preclude study


- PT/PTT no greater than 1.5 times upper limit of normal (ULN)

- AST/ALT less than 1.5 times ULN

- Alkaline phosphatase less than 1.5 times ULN

- No chronic or acute hepatic disorder

- No abnormal hepatic laboratory test result that would preclude study


- Creatinine no greater than 1.5 times ULN

- No chronic or acute renal disorder

- No other abnormal renal laboratory test result that would preclude study


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No prior or concurrent active inflammatory bowel disease (e.g., Crohn's disease or
ulcerative colitis)

- No other prior or concurrent curatively treated malignancy with a survival prognosis
of less than 5 years

- No hypersensitivity or adverse reaction to COX-2 inhibitors (e.g., celecoxib),
sulfonamides, salicylates, or NSAIDs

- No other significant medical, psychological, or psychosocial condition that would
preclude study participation


Biologic therapy:

- Not specified


- Not specified

Endocrine therapy:

- At least 6 months since prior regular (at least 2 weeks duration) oral or intravenous

- At least 6 months since prior regular (at least 4 weeks duration) inhaled

- No concurrent regular oral or intravenous corticosteroids

- No concurrent regular inhaled corticosteroids

- Concurrent corticosteroid nasal spray allowed


- At least 12 weeks since prior radiotherapy to the chest or upper abdomen


- At least 3 months since prior surgery to the esophagus or stomach except hiatal
hernia repair, fundoplication, vagotomy, or pyloroplasty

- No prior complete mucosal resection using any technique

- No concurrent resection of high-grade nodule


- At least 30 days since prior chronic (at least 3 times a week for greater than 2
weeks) aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) (i.e., greater
than 100 mg/day)

- No prior complete mucosal ablation using any technique

- No prior treatment on this study

- At least 30 days since prior investigational medication including shingles vaccine

- No concurrent chronic NSAIDs or COX-2 inhibitors except low-dose aspirin (i.e., no
greater than 100 mg/day)

- No concurrent anticoagulants (e.g., heparin or warfarin)

- No other concurrent investigational medication

Type of Study:


Study Design:

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention

Principal Investigator

Arlene A. Forastiere, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Sidney Kimmel Comprehensive Cancer Center


United States: Federal Government

Study ID:

JHOC-J9932, CDR0000067917



Start Date:

July 2000

Completion Date:

Related Keywords:

  • Esophageal Cancer
  • esophageal cancer
  • Barrett Esophagus
  • Esophageal Diseases
  • Esophageal Neoplasms



Mayo Clinic Cancer Center Rochester, Minnesota  55905
Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781
Ireland Cancer Center Cleveland, Ohio  44106-5065
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland  21231-2410
Veterans Affairs Medical Center - Tucson Tucson, Arizona  85723
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital) Hines, Illinois  60141
Herbert Irving Comprehensive Cancer Center New York, New York  10032
Veterans Affairs Medical Center - Portland Portland, Oregon  97207